heterocycloalkyl; C^a and C^b are carbon atoms, which are adjacent to each other and are part of ring A; Z is 5- or 6-membered heteroaryl; R^5 is chosen from H, acyl, C_1-C_6 alkyl, and C_3-C_6 cycloalkyl; W is chosen from C_1-C_4 alkylene, wherein the alkylene is optionally substituted with 1 - 4 substituents independently chosen from alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, C_3-C_6-cycloalkyl, 3- to 8-membered heterocycloalkyl, aryl, 5- or 6-membered heteroaryl, CN, halogen, OR^{42}, SR^{42}, $NR^{42}R^{43}$, $C(O)R^{44}$, $C(O)NR^{42}R^{43}$, $OC(O)NR^{42}R^{43}$, $C(O)OR^{42}$, $NR^{45}C(O)R^{44}$, $NR^{45}C(O)OR^{42}$, $NR^{45}C(O)NR^{42}R^{43}$, $NR^{45}C(S)NR^{42}R^{43}$, $NR^{45}S(O)_2R^{44}$, $S(O)_2NR^{42}R^{43}$, $S(O)R^{44}$, and $S(O)_2R^{44}$, wherein R^{42}, R^{43} and R^{45} are members independently chosen from H, acyl, C_1-C_6-alkyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C_3-C_8 cycloalkyl and 3- to 8-membered heterocycloalkyl, wherein R^{42} and R^{43}, together with the nitrogen atom to which they are bound are optionally joined to form a 5- to 7-membered heterocyclic ring; and R^{44} is independently chosen from acyl, C_1-C_6-alkyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C_3-C_8 cycloalkyl and 3- to 8-membered heterocycloalkyl; Cy is chosen from cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, wherein the cycloalkyl, heterocycloalkyl, aryl or heteroaryl is optionally substituted with 1 - 6 substituents independently chosen from substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, haloalkyl, substituted or unsubstituted heteroalkyl , substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl , substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, CN, halogen, OR^{52}, SR^{52}, $NR^{52}R^{53}$, $C(O)R^{54}$, $C(O)NR^{52}R^{53}$, $OC(O)NR^{52}R^{53}$, $C(O)OR^{52}$, $NR^{55}C(O)R^{54}$, $NR^{55}C(O)OR^{52}$, $NR^{55}C(O)NR^{52}R^{53}$, $NR^{55}C(S)NR^{52}R^{53}$, $NR^{55}S(O)_2R^{54}$, $S(O)_2NR^{52}R^{53}$, $S(O)R^{54}$ and $S(O)_2R^{54}$, wherein R^{52}, R^{53} and R^{55} are independently chosen from H, acyl, C_1-C_6-alkyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C_3-C_8 cycloalkyl and 3- to 8-membered heterocycloalkyl, wherein R^{52} and R^{53}, together with the nitrogen atom to which they are bound are optionally joined to form a 5- to 7-membered heterocyclic ring; andR^{54} is independently chosen from acyl, C_1-C_6-alkyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C_3-C_8 cycloalkyl and 3- to 8-membered heterocycloalkyl. In one example, the method further comprises measuring phosphorylated kinase substrate, such as phospho-cJun.

[0020a] The present invention also provides a compound chosen from:

N-(2-(1*H*-1,2,4-triazol-5-yl)thiophen-3-yl)-2-(naphthalen-1-yl)acetamide;

N-(2-(3-methyl-1*H*-1,2,4-triazol-5-yl)thiophen-3-yl)-2-(naphthalen-1-yl)acetamide;

N-(2-(1,3-dimethyl- 1*H*-1 ,2,4-triazol-5-yl)thiophen-3-yl)-2-(naphthalen-1-yl)acetamide;

N-(2-(1 -methyl-1*H*-1,2,4-triazol-5-yl)thiophen-3-yl)-2-(naphthalen-1-yl)acetamide;

2-(4-methoxyphenyl)-*N*-(2-(3-methyl-1*H*-1,2,4-triazol-5-yl)thiophen-3-yl)acetamide;

N-(2-(1*H*-1,2,4-triazol-5-yl)thiophen-3-yl)-2-(4-methoxyphenyl)acetamide;

N-(2-(1*H*-1,2,4-triazol-1-yl)thiophen-3-yl)-2-(4-methoxyphenyl)acetamide;

2-(4-methoxyphenyl)-*N*-(4-methyl-3-(3-methyl-1H-1,2,4-triazol-5-yl)thiophen-2- yl)acetamide;

N-(2-(2*H*-1,2,3-triazol-2-yl)thiophen-3-yl)-2-(4-methoxyphenyl)acetamide;

N-(2-(3-cyclopropyl-1*H*-1,2,4-triazol-5-yl)thiophen-3-yl)-2-(4-methoxyphenyl)acetamide;

N-(2-(3-ethyl-1*H*-1,2,4-triazol-5-yl)thiophen-3-yl)-2-(4-methoxyphenyl)acetamide;

N-(2-(3-tert-butyl-1*H*-1,2,4-triazol-5-yl)thiophen-3-yl)-2-(4-methoxyphenyl)acetamide;

2-(4-methoxyphenyl)-N-(2-(3-(tetrahydrofuran-2-yl)-1*H*-1,2,4-triazol-5-yl)thiophen-3-yl)acetamide;

2-(4-methoxyphenyl)-N-(2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)thiophen-3- yl)acetamide;

N-(4-methyl-3-(1*H*-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(2-oxo-3,4-dihydroquinolin-1(2*H*)-yl)acetamide;

N-(4-methyl-3-(3-methyl-1*H*-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(2-oxo-3,4-dihydroquinolin-1(2*H*)-yl)acetamide;

2-(4-methoxyphenyl)-*N*-(2-(3-(pyridin-4-yl)-1*H*-1,2,4-triazol-5-yl)thiophen-3-yl)acetamide;

N-(2-(3-amino-1*H*-1,2,4-triazol-5-yl)thiophen-3-yl)-2-(4-methoxyphenyl)acetamide;

N-(4-chloro-3-(1*H*-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(2-oxo-3,4-dihydroquinolin-1(2*H*)-yl)acetamide;

N-(3-(1*H*-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(2-oxo-3,4-dihydroquinolin-1(2H)-yl)acetamide;

N-(4-chloro-3-(1*H*-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(isoquinolin-5-yl)acetamide;

N-(4-chloro-3-(1*H*-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(quinolin-5-yl)acetamide;

N-(2-(1*H*-1,2,4-triazol-5-yl)thiophen-3-yl)-2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)acetamide;

N-(4-methyl-3-(1*H*-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(quinolin-5-yl)acetamide

2-(2,3-dihydrobenzo[6] [1,4] dioxin-6-yl)-N-(2-(3-methyl-1H-1,2,4-triazol-5-yl)thiophen-3-yl)acetamide;

N-(2-(1*H*-1,2,4-triazol-5-yl)thiophen-3-yl)-2-(quinolin-5-yl)acetamide;

N-(4-methyl-3-(3-methyl-1*H*-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(quinolin-5-yl)acetamide;

N-(4-methyl-3-(1*H*-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(quinoxalin-5-yl)acetamide;
N-(4-methyl-3-(3-methyl-1*H*-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(quinoxalin-5-yl)acetamide;
N-(4-methyl-3-(1*H*-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(4-(3-(piperidin-1-yl)propoxy)phenyl)acetamide;
N-(4-methyl-3-(3-methyl-1*H*-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(4-(3-(piperidin-1-yl)propoxy)phenyl)acetamide;
2-(4-(2-(1*H*-imidazol-1-yl)ethoxy)phenyl)-*N*-(4-methyl-3-(1*H*-1,2,4-triazol-5-yl)thiophen-2-yl)acetamide;
N-(4-bromo-3-(1*H*-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(isoquinolin-5-yl)acetamide;
N-(4-bromo-3-(1*H*-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(quinolin-5-yl)acetamide;
N-(4-bromo-3-(1*H*-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(2-oxo-3,4-dihydroquinolin-1(2*H*)-yl)acetamide;
N-(4-cyano-3-(1*H*-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(isoquinolin-5-yl)acetamide;
N-(4-cyano-3-(1*H*-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(2-oxo-3,4-dihydroquinolin-1(2*H*)-yl)acetamide;
N-(2-(3-methyl-1*H*-1,2,4-triazol-5-yl)thiophen-3-yl)-2-(4-(2-oxopyrrolidin-1-yl)phenyl)acetamide;
N-(4-methyl-3-(5-methyl-4*H*-1,2,4-triazol-3-yl)thiophen-2-yl)-2-(4-(pyridin-4-yl)phenyl)acetamide;
N-(4-cyano-3-(4*H*-1,2,4-triazol-3-yl)thiophen-2-yl)-2-(quinolin-5-yl)acetamide;
N-(4-bromo-3-(1*H*-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(2-oxo-7-(trifluoromethyl)quinolin-1(2*H*)-yl)acetamide;
N-(4-bromo-3-(1*H*-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(6-fluoro-2-oxo-3,4-dihydroquinolin- 1 (2*H*)-yl)acetamide;
N-(4-bromo-3-(1H-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(7-fluoro-2-oxoquinolin-1(2*H*)-yl)acetamide;
N-(4-bromo-3-(1*H*-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(7-chloro-2-oxo-3,4-dihydroquinolin-1(2*H*)-yl)acetamide;
N-(4-bromo-3-(1*H*-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(6,7-difluoro-2-oxoquinolin-1(2*H*)-yl)acetamide;

N-(4-bromo-3-(1*H*-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(2-oxo-6-(trifluoromethyl)quinolin-1(2*H*)-yl)acetamide;
N-(4-bromo-3-(1*H*-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(6-fluoro-2-oxoquinolin-1(2*H*)-yl)acetamide;

2-(isoquinolin-5-yl)-*N*-(2-(4-methylthiazol-2-yl)thiophen-3-yl)acetamide;

2-(isoquinolin-5-yl)-*N*-(2-(thiazol-4-yl)thiophen-3-yl)acetamide;

2-(2-oxo-3,4-dihydro-1,6-naphthyridin-1(2*H*)-yl)-*N*-(2-(thiazol-4-yl)thiophen-3-yl)acetamide;

2-(2-oxo-3,4-dihydroquinolin-l(2*H*)-yl)-*N*-(2-(thiazol-4-yl)thiophen-3-yl)acetamide;

2-(isoquinolin-5-yl)-*N*-(2-(2-methoxythiazol-4-yl)thiophen-3-yl)acetamide;

N-(2-(2-chlorothiazol-4-yl)thiophen-3-yl)-2-(isoquinolin-5-yl)acetamide;

2-(isoquinolin-5-yl)-N-(2-(thiazol-2-yl)thiophen-3-yl)acetamide;

2-(isoquinolin-5-yl)-*N*-(2-(5-methylthiazol-2-yl)thiophen-3-yl)acetamide;

2-(4-(3-(piperidin-l-yl)propoxy)phenyl)-*N*-(2-(thiazol-4-yl)thiophen-3-yl)acetamide;

N-(3-(benzo[*d*]thiazol-2-yl)-4-methylthiophen-2-yl)-2-(isoquinolin-5-yl)acetamide;

2-(4-methoxyphenyl)-*N*-(2-(oxazol-2-yl)thiophen-3-yl)acetamide;

2-(isoquinolin-5-yl)-*N*-(2-(oxazol-2-yl)thiophen-3-yl)acetamide;

2-(4-methoxyphenyl)-*N*-(3-(5-methyl-l,2,4-oxadiazol-3-yl)thiophen-2-yl)acetamide;

N-(2-(l,3,4-oxadiazol-2-yl)thiophen-3-yl)-2-(naphthalen-l-yl)acetamide;

2-(4-methoxyphenyl)-N-(2-(5-methyl-l,3,4-oxadiazol-2-yl)thiophen-3-yl)acetamide;

N-(2-(5-isopropyl-l,3,4-oxadiazol-2-yl)thiophen-3-yl)-2-(4-methoxyphenyl)acetamide;

N-(2-(5-methyl-1,3,4-oxadiazol-2-yl)thiophen-3-yl)-2-(naphthalen-1-yl)acetamide;

N-(4-methyl-3-(3-methyl-l,2,4-oxadiazol-5-yl)thiophen-2-yl)-2-(naphthalen-l-yl)acetamide;

N-(4-methyl-3-(3-methyl-l,2,4-oxadiazol-5-yl)thiophen-2-yl)-2-(4-(pyridin-4-yl)phenyl)acetamide;

N-(2-(3-methyl-l,2,4-oxadiazol-5-yl)thiophen-3-yl)-2-(naphthalen-l-yl)acetamide;

N-(4-(l*H*-l,2,4-triazol-5-yl)thiazol-5-yl)-2-(isoquinolin-5-yl)acetamide;

2-(isoquinolin-5-yl)-*N*-(4-(l-methyl-1*H*-1,2,4-triazol-5-yl)thiazol-5-yl)acetamide;

2-(2-pyridyl)-3-(1-naphthylacetylamino)thiophene;

N-(2-(l*H*-pyrazol-1-yl)thiophen-3-yl)-2-(4-methoxyphenyl)-acetamide;

2-(4-methoxyphenyl)-*N*-(2-(4-methyl-l*H*-pyrazol-1-yl)thiophen-3-yl)acetamide;

N-(2-(l*H*-pyrazol-3-yl)thiophen-3-yl)-2-(naphthalen-l-yl)acetamide;

N-(2-(1-methyl-l*H*-pyrazol-3-yl)thiophen-3-yl)-2-(naphthalen-1-yl)acetamide;

N-(2-(5-methyl-l*H*-pyrazol-3-yl)thiophen-3-yl)-2-(naphthalen-1-yl)acetamide;

N-(3-(2*H*-tetrazol-5-yl)thiophen-2-yl)-2-(4-methoxyphenyl)-acetamide;

2-(4-methoxyphenyl)-*N*-(3-(2-methyl-2*H*-tetrazol-5-yl)thiophen-2-yl)acetamide;

N-(3-(2-(methoxymethyl)-2*H*-tetrazol-5-yl)thiophen-2-yl)-2-(4-methoxyphenyl)acetamide;

N-(3-(1-(methoxymethyl)- l*H*-tetrazol-5-yl)thiophen-2-yl)-2-(4-methoxyphenyl)acetamide;

N-(2-(1-methyl-l*H*-imidazol-2-yl)thiophen-3 -yl)-2-(naphthalen-1-yl)acetamide;

2-(4-methoxyphenyl)-*N*-(2-(l-methyl-lH-imidazol-4-yl)thiophen-3-yl)acetamide;

N-(2-(l*H*-imidazol-4-yl)thiophen-3-yl)-2-(4-methoxyphenyl)-acetamide;

N-(2-(l*H*-imidazol-4-yl)thiophen-3-yl)-2-(2-oxo-3,4-dihydroquinolin-l(2*H*)-yl)acetamide;

2-(4-methoxyphenyl)-*N*-(2-(2-methyl-l*H*-imidazol-4-yl)thiophen-3-yl)acetamide;

N-(2-(2-methyl-l*H*-imidazol-4-yl)thiophen-3-yl)-2-(2-oxo-3,4-dihydroquinolin-l(2*H*)-yl)acetamide;

N-(2-(l*H*-imidazol- 1 -yl)thiophen-3-yl)2-(naphthalen-1-yl)acetamide;

2-(4-methoxyphenyl)-*N*-(2-(4-methyl-l*H*-imidazol-l-yl)thiophen-3-yl)acetamide;

2-(4-methoxyphenyl)-*N*-(2-(pyrazin-2-yl)thiophen-3-yl)acetamide;

2-(isoquinolin-5-yl)-*N*-(4-(pyrazin-2-yl)thiazol-5-yl)acetamide;

N-(4,4'-bithiazol-5-yl)-2-(isoquinolin-5-yl)acetamide;

2-(4-methoxyphenyl)-*N*-(2-(2-oxooxazolidin-3-yl)thiophen-3-yl)acetamide;

2-(7-bromo-2-oxo-3,4-dihydroquinolin-l(2*H*)-yl)-*N*-(4-bromo-3-(lH-l,2,4-triazol-5-yl)thiophen-2-yl)acetamide;

N-(4-bromo-3-(4H-l,2,4-triazol-3-yl)thiophen-2-yl)-2-(quinolin-4-yl)acetamide;

N-(4-bromo-3-(lH-l,2,4-triazol-5-yl)thiophen-2-yl)-2-(2-oxo-6-(trifluoromethyl)quinolin-1(2H)-yl)acetamide;

N-(4-bromo-3-(lH-l,2,4-triazol-5-yl)thiophen-2-yl)-2-(8-fluoroisoquinolin-5-yl)acetamide;

N-(4-bromo-3-(lH-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(2-oxo-1 ,6-naphthyridin-1(2H)-yl)acetamide;

N-(4-bromo-3-(lH-l,2,4-triazol-5-yl)thiophen-2-yl)-2-(8-fluoroquinolin-5-yl)acetamide;

N-(4-bromo-3-(4H-l,2,4-triazol-3-yl)thiophen-2-yl)-2-(7-(trifluoromethyl)quinolin-5-yl)acetamide;

N-(4-bromo-3-(4H-l,2,4-triazol-3-yl)thiophen-2-yl)-2-(5-(trifluoromethyl)quinolin-7-yl)acetamide;

N-(4-bromo-3-(lH-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(2-oxo-1,5-naphthyridin-1(2H)-yl)acetamide;

N-(4-bromo-3-(lH-l,2,4-triazol-5-yl)thiophen-2-yl)-2-(2-oxo-3,4-dihydro-l,6-naphthyridin-1(2H)-yl)acetamide;

N-(4-bromo-3-(lH-l,2,4-triazol-5-yl)thiophen-2-yl)-2-(2-oxo-3,4-dihydro-l,5-naphthyridin-1(2H)-yl)acetamide;

N-(4-bromo-3-(lH-l,2,4-triazol-5-yl)thiophen-2-yl)-2-(6-chloro-2-oxoquinolin-l(2H)-yl)acetamide;

N-(4-bromo-3-(lH-l,2,4-triazol-5-yl)thiophen-2-yl)-2-(5-fluoro-2-oxoquinolin-l(2H)-yl)acetamide;

N-(4-bromo-3-(lH-l,2,4-triazol-3-yl)thiophen-2-yl)-2-(3-fluoroquinolin-8-yl)acetamide;

N-(4-bromo-3-(lH-l,2,4-triazol-5-yl)thiophen-2-yl)-2-(2-oxo-6-(trifluoromethoxy)quinolin- 1 (2H)-yl)acetamide;

N-(4-bromo-3-(4H-l,2,4-triazol-3-yl)thiophen-2-yl)-2-(isoquinolin-4-yl)acetamide;

N-(5-chloro-3-(lH-l,2,4-triazol-5-yl)thiophen-2-yl)-2-(2-oxo-6-(trifluoromethyl)quinolin-1(2H)-yl)acetamide;

N-(4-bromo-3-(lH-l,2,4-triazol-3-yl)thiophen-2-yl)-2-(3-fluoroquinolin-5-yl)acetamide;

N-(4-bromo-3-(lH-l,2,4-triazol-5-yl)thiophen-2-yl)-2-(2-oxo-7-(trifluoromethoxy)quinolin- 1 (2H)-yl)acetamide;

N-(4-bromo-3-(lH-l,2,4-triazol-5-yl)thiophen-2-yl)-2-(7-cyano-2-oxoquinolin-l(2H)-yl)acetamide;

N-(4-bromo-3-(lH-l,2,4-triazol-5-yl)thiophen-2-yl)-2-(isoquinolin-8-yl)acetamide;

N-(4-bromo-3-(lH-l,2,4-triazol-5-yl)thiophen-2-yl)-2-(6-cyano-2-oxoquinolin-l(2H)-yl)acetamide;

N-(4-bromo-3-(lH-l,2,4-triazol-5-yl)thiophen-2-yl)-2-(quinolin-8-yl)acetamide;

N-(4-bromo-3-(lH-l,2,4-triazol-5-yl)thiophen-2-yl)-2-(2-oxo-5-(trifluoromethyl)quinolin- 1 (2H)-yl)acetamide;

N-(4-bromo-3-(lH-l,2,4-triazol-5-yl)thiophen-2-yl)-2-(2-oxo-6-(trifluoromethyl)-3,4-dihydroquinolin- 1 (2H)-yl)acetamide;

N-(4-cyano-3-(1 -methyl- IH- 1,2,4-triazol-3-yl)thiophen-2-yl)-2-(quinolin-5-yl)acetamide;

N-(4-bromo-3-(lH-l,2,4-triazol-3-yl)thiophen-2-yl)-2-(2-(trifluoromethyl)quinolin-7-yl)acetamide;

N-(4-bromo-3-(lH-l,2,4-triazol-5-yl)thiophen-2-yl)-2-(7-fluoroquinolin-5-yl)acetamide;

N-(4-bromo-3-(lH-l,2,4-triazol-3-yl)thiophen-2-yl)-2-(3-(trifluoromethyl)quinolin-5-yl)acetamide;

N-(4-bromo-3-(lH-l,2,4-triazol-5-yl)thiophen-2-yl)-2-(6-fluoroquinolin-5-yl)acetamide;

N-(4-bromo-3-(lH-l,2,4-triazol-5-yl)thiophen-2-yl)-2-(6-fluoroquinolin-7-yl)acetamide;

N-(4-bromo-3-(lH-l,2,4-triazol-5-yl)thiophen-2-yl)-2-(6-ethynyl-2-oxoquinolin-l(2H)-yl)acetamide;

N-(4-bromo-3-(lH-l,2,4-triazol-5-yl)thiophen-2-yl)-2-(2-oxo-7-(trifluoromethyl)-l,6-naphthyridin-1(2H)-yl)acetamide;

N-(4-bromo-3-(lH-l,2,4-triazol-5-yl)thiophen-2-yl)-2-(5-oxopyrazolo[l,5-a]pyrimidin-4(5H)-yl)acetamide;

N-(4-bromo-3-(lH-l,2,4-triazol-3-yl)thiophen-2-yl)-2-(3-(trifluoromethyl)quinolin-8-yl)acetamide;
N-(4-bromo-3-(lH-l,2,4-triazol-5-yl)thiophen-2-yl)-2-(6-methylimidazo[2,l-b]thiazol-3-yl)acetamide;
2-(2-oxo-6-(trifluoromethyl)quinolin-l(2H)-yl)-N-(2-(thiazol-4-yl)thiophen-3-yl)acetamide;
N-(4-cyano-3-(pyrazin-2-yl)thiophen-2-yl)-2-(quinolin-5-yl)acetamide;
2-(2-oxo-l,6-naphthyridin-l(2H)-yl)-N-(2-(thiazol-4-yl)thiophen-3-yl)acetamide;
N-(4-bromo-3-(4H-l,2,4-triazol-3-yl)thiophen-2-yl)-2-(3,3-difluoro-2-oxoindolin-l-yl)acetamide;
2-(benzo[d]thiazol-7-yl)-N-(4-bromo-3-(lH-l,2,4-triazol-5-yl)thiophen-2-yl)acetamide;
N-(4-chloro-3-(lH-l,2,4-triazol-5-yl)thiophen-2-yl)-2-(2-oxo-6-(trifluoromethyl)quinolin-1(2H)-yl)acetamide;
N-(4-cyano-3-(oxazol-2-yl)thiophen-2-yl)-2-(2-oxo-6-(trifluoromethyl)quinolin-l(2H)-yl)acetamide;
N-(4-bromo-3-(lH-l,2,4-triazol-5-yl)thiophen-2-yl)-2-(2-oxo-6-(trifluoromethyl)-l,5-naphthyridin- 1(2H)-yl)acetamide;
N-(3-(l,2,4-oxadiazol-3-yl)thiophen-2-yl)-2-(6,7-difluoro-2-oxoquinolin-l(2H)-yl)acetamide;
N-(4-cyano-3-(thiazol-2-yl)thiophen-2-yl)-2-(2-oxo-6-(trifluoromethyl)quinolin-l(2H)-yl)acetamide;
N-(4-bromo-3-(lH-l,2,4-triazol-5-yl)thiophen-2-yl)-2-(5-oxo-2-(trifluoromethyl)pyrazolo[1 ,5-a]pyrimidin-4(5H)-yl)acetamide;
N-(4-cyano-3-(thiazol-4-yl)thiophen-2-yl)-2-(2-oxo-6-(trifluoromethyl)quinolin-l(2H)-yl)acetamide;
N-(4-bromo-3-(lH-l,2,4-triazol-5-yl)thiophen-2-yl)-2-(imidazo[l,2-a]pyridin-5-yl)acetamide;
N-(4-bromo-3-(lH-l,2,4-triazol-5-yl)thiophen-2-yl)-2-(7-fluoro-2-oxo-6-(trifluoromethyl)quinolin-1(2H)-yl)acetamide;
N-(4-bromo-3-(1-methyl-1H-1,2,4-triazol-3-yl)thiophen-2-yl)-2-(2-oxo-3,4-dihydro-1,5-naphthyridin-1(2H)-yl)acetamide;
N-(4-cyano-3-(thiazol-5-yl)thiophen-2-yl)-2-(2-oxo-6-(trifluoromethyl)quinolin-l(2H)-yl)acetamide;
N-(4-cyano-3-(lH-l,2,3-triazol-l-yl)thiophen-2-yl)-2-(2-oxo-6-

(trifluoromethyl)quinolin-1(2H)-yl)acetamide;
N-(3-(lH-benzo[d][l,2,3]triazol-l-yl)-4-cyanothiophen-2-yl)-2-(2-oxo-6-(trifluoromethyl)quinolin-1(2H)-yl)acetamide;
N-(4-bromo-3-(lH-l,2,4-triazol-5-yl)thioplien-2-yl)-2-(6-fluoroisoquinolin-5-yl)acetamide; and N-(4-bromo-3-(lH-l,2,4-triazol-5-yl)thiophen-2-yl)-2-(6-fluoroisoquinolin-7-yl)acetamide;
N-(4-cyano-3-(2H-1,2,3 -triazol-2-yl)thiophen-2-yl)-2-(2-oxo-6-(trifluoromethyl)quinolin-1(2H)-yl)acetamide;
N-(4-chloro-3-(1H-1,2,4-triazol-3 -yl)thiophen-2-yl)-2-(2-oxo-3,4-dihydro-1,5-naphthyridin-1(2H)-yl)acetamide;
N-(4-cyano-3-(thiazol-2-yl)thiophen-2-yl)-2-(2-oxo-3,4-dihydro-1,5-naphthyridin-1(2H)-yl)acetamide;
N-(4-chloro-3-(l-methyl-lH-l,2,4-triazol-3-yl)thiophen-2-yl)-2-(2-oxo-3,4-dihydro-l,5-naphthyridin-1(2H)-yl)acetamide;
N-(4-chloro-3 -(1 H- 1 ,2,4-triazol-5 -yl)thiophen-2-yl)-2-(5-oxopyrazolo[1,5-a]pyrimidin-4(5H)-yl)acetamide;
N-(4-bromo-3-(oxazol-2-yl)thioplien-2-yl)-2-(2-oxo-3,4-dihydro-1,5-naphthyridin-l(2H)-yl)acetamide;
N-(4-bromo-3-(thiazol-2-yl)thiophen-2-yl)-2-(2-oxo-3,4-dihydro-l,5-naphthyridin-l(2H)-yl)acetamide;
N-(4-chloro-3-(thiazol-2-yl)thiophen-2-yl)-2-(2-oxo-3,4-dihydro-l,5-naphthyridin-l(2H)-yl)acetamide;
N-(3-(benzo[d]thiazol-2-yl)-4-cyanothiophen-2-yl)-2-(2-oxo-3,4-dihydro-1,5-naphthyridin-1(2H)-yl)acetamide;
N-(4-chloro-3-(3-methyl-lH-l,2,4-triazol-5-yl)thiophen-2-yl)-2-(2-oxo-3,4-dihydro-l,5-naphthyridin-1(2H)-yl)acetamide;
N-(4-chloro-3-(l-(3-(dimethylamino)propyl)-lH-l,2,4-triazol-3-yl)thiophen-2-yl)-2-(2-oxo-6-(trifluoromethyl)quinolin-1(2H)-yl)acetamide;
N-(4-chloro-3-(1-(3-(4-methylpiperazin-1-yl)propyl)-1H-1 ,2,4-triazol-3-yl)thiophen-2-yl)-2-(2-oxo-6-(trifluoromethyl)quinolin-l(2H)-yl)acetamide;
N-(4-chloro-3-(3-ethyl-lH-l,2,4-triazol-5-yl)thiophen-2-yl)-2-(2-oxo-3,4-dihydro-l,5-naphthyridin-1(2H)-yl)acetamide;

N-(4-chloro-3-(1-(2-(dimethylamino)ethyl)-1H-1,2,4-triazol-3-yl)thiophen-2-yl)-2-(2-oxo-6-(trifluoromethyl)quinolin-1(2H)-yl)acetamide;

N-(4-chloro-3-(1H-1,2,4-triazol-3-yl)thiophen-2-yl)-N-(2-(dimethylamino)ethyl)-2-(2-oxo-6-(trifluoromethyl)quinolin-1(2H)-yl)acetamide;

N-(4-cyano-3-(1H-1,2,4-triazol-3 -yl)thiophen-2-yl)-2-(2-oxo-3,4-dihydro-1,5-naphthyridin-1(2H)-yl)acetamide;

N-(4-chloro-3-(1-methyl-1H-1,2,4-triazol-3-yl)thiophen-2-yl)-2-(5-oxopyrazolo[1,5-a]pyrimidin-4(5H)-yl)acetamide;

N-(4-chloro-3-(1-(3-morpholinopropyl)-1H-1,2,4-triazol-3-yl)thiophen-2-yl)-2-(2-oxo-6-(trifluoromethyl)quinolin-1(2H)-yl)acetamide;

N-(4-chloro-3-(1H-1,2,4-triazol-3-yl)thiophen-2-yl)-2-(2-oxo-6-(trifluoromethyl)quinolin-1(2H)-yl)-N-(3-(pyrrolidin-1-yl)propyl)acetamide;

N-(4-chloro-3-(1-(3-(pyrrolidin-1-yl)propyl)-1H-1,2,4-triazol-3-yl)thiophen-2-yl)-2-(2-oxo-6-(trifluoromethyl)quinolin-1(2H)-yl)acetamide;

N-(4-chloro-3-(1-methyl-1H-1,2,4-triazol-3-yl)thiophen-2-yl)-2-(2-oxo-6-(trifluoromethyl)-1,5-naphthyridin-1(2H)-yl)acetamide;

N-(4-chloro-3-(1H-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(8-(trifluoromethyl)quinolin-5-yl)acetamide;

N-(4-bromo-3-(2H-1,2,3-triazol-2-yl)thiophen-2-yl)-2-(2-oxo-6-(trifluoromethyl)quinolin-1(2H)-yl)acetamide;

N-(4-chloro-3-(1H-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(2-oxo-6-(trifluoromethyl)-1,5-naphthyridin-1(2H)-yl)acetamide;

N-(4-chloro-3-(3-isopropyl-1H-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(2-oxo-3,4-dihydro-1,5-naphthyridin-1(2H)-yl)acetamide;

2-(6-bromo-2-oxoquinolin-1(2H)-yl)-N-(4-bromo-3-(1H-1,2,4-triazol-3-yl)thiophen-2-yl)acetamide;

N-(4-cyano-3-(1-methyl-1H-1,2,4-triazol-3-yl)thiophen-2-yl)-2-(2-oxo-3,4-dihydro-1,5-naphthyridin-1(2H)-yl)acetamide;

2-(6-bromo-2-oxoquinolin-1(2H)-yl)-N-(4-chloro-3-(1H-1,2,4-triazol-3-yl)thiophen-2-yl)acetamide;

N-(4-chloro-3 -(1 H- 1 ,2,4-triazol-3 -yl)thiophen-2-yl)-2-(6-cyano-2-oxoquinolin-1(2H)-yl)acetamide;


N-(4-chloro-3-(1H-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(5-oxo-2-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-4(5H)-yl)acetamide;

N-(4-chloro-3-(lH-l,2,4-triazol-3-yl)thiophen-2-yl)-2-(2-oxo-7-(trifluoromethyl)-l,6-naphthyridin-1(2H)-yl)acetamide;
N-(4-chloro-3-(1-methyl-1H-1,2,4-triazol-3-yl)thiophen-2-yl)-2-(5-oxo-2-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-4(5H)-yl)acetamide; and
N-(4-chloro-3-(1-methyl-1H-1,2,4-triazol-3-yl)thiophen-2-yl)-2-(2-oxo-7-(trifluoromethyl)-1,6-naphthyridin-1(2H)-yl)acetamide,

or a pharmaceutically acceptable salt thereof.

[0020b] The present invention also provides a pharmaceutical composition comprising a compound as described herein and a pharmaceutically acceptable carrier.

[0020c] The present invention also provides a use of a pharmaceutically effective amount of a compound having a structure according to Formula (I):



(I)

or a salt or solvate thereof,

wherein

ring A is 5-membered heteroaryl comprising a sulfur atom, wherein the heteroaryl is optionally substituted with 1 or 2 substituents independently chosen from alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, C_3-C_{10}-cycloalkyl, 3- to 8-membered heterocycloalkyl, aryl, 5- or 6-membered heteroaryl, CN, halogen, OR^{12}, SR^{12}, $NR^{12}R^{13}$, $C(O)R^{14}$, $C(O)NR^{12}R^{13}$, $OC(O)NR^{12}R^{13}$, $C(O)OR^{12}$, $NR^{15}C(O)R^{14}$, $NR^{15}C(O)OR^{12}$, $NR^{15}C(O)NR^{12}R^{13}$, $NR^{15}C(S)NR^{12}R^{13}$, $NR^{15}S(O)_2R^{14}$, $S(O)_2NR^{12}R^{13}$, $S(O)R^{14}$ and $S(O)_2R^{14}$,

wherein

R^{12}, R^{13} and R^{15} are independently chosen from H, acyl, C_1-C_6-alkyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C_3-C_8

cycloalkyl and 3- to 8-membered heterocycloalkyl, or R^{12} and R^{13}, together with the nitrogen atom to which they are bound form a 5- to 7-membered heterocyclic ring; and

R^{14} is chosen from acyl, C_1-C_6-alkyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6- membered heteroaryl, C3-C8 cycloalkyl and 3- to 8-membered heterocycloalkyl;

C^a and C^b are carbon atoms, which are adjacent to each other and are part of ring A;

Z is 5- or 6-membered heteroaryl;

R^5 is chosen from H, acyl, C_1-C_6 alkyl, and C_3-C_6 cycloalkyl;

W is chosen from C_1-C_4 alkylene, wherein the alkylene is optionally substituted with 1 – 4 substituents independently chosen from alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, C_3-C_6-cycloalkyl, 3- to 8-membered heterocycloalkyl, aryl, 5- or 6-membered heteroaryl, CN, halogen, OR^{42}, SR^{42}, $NR^{42}R^{43}$, $C(O)R^{44}$, $C(O)NR^{42}R^{43}$, $OC(O)NR^{42}R^{43}$, $C(O)OR^{42}$, $NR^{45}C(O)R^{44}$, $NR^{45}C(O)OR^{42}$, $NR^{45}C(O)NR^{42}R^{43}$, $NR^{45}C(S)NR^{42}R^{43}$, $NR^{45}S(O)_2R^{44}$, $S(O)_2NR^{42}R^{43}$, $S(O)R^{44}$, and $S(O)_2R^{44}$, wherein

R^{42}, R^{43} and R^{45} are members independently chosen from H, acyl, C_1-C_6-alkyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C_3-C_8 cycloalkyl and 3- to 8-membered heterocycloalkyl, wherein R^{42} and R^{43}, together with the nitrogen atom to which they are bound are optionally joined to form a 5- to 7-membered heterocyclic ring; and

R^{44} is independently chosen from acyl, C_1-C_6-alkyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C_3-C_8 cycloalkyl and 3- to 8-membered heterocycloalkyl;

Cy is chosen from cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, wherein the cycloalkyl, heterocycloalkyl, aryl or heteroaryl is optionally substituted with 1 - 6 substituents independently chosen from substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, haloalkyl, substituted or unsubstituted heteroalkyl , substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl , substituted or unsubstituted aryl, substituted or unsubstituted


heteroaryl, CN, halogen, OR^{52}, SR^{52}, $NR^{52}R^{53}$, $C(O)R^{54}$, $C(O)NR^{52}R^{53}$, $OC(O)NR^{52}R^{53}$, $C(O)OR^{52}$, $NR^{55}C(O)R^{54}$, $NR^{55}C(O)OR^{52}$, $NR^{55}C(O)NR^{52}R^{53}$, $NR^{55}C(S)NR^{52}R^{53}$, $NR^{55}S(O)_2R^{54}$, $S(O)_2NR^{52}R^{53}$, $S(O)R^{54}$ and $S(O)_2R^{54}$,

wherein

R^{52}, R^{53} and R^{55} are independently chosen from H, acyl, C_1-C_6-alkyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C_3-C_8 cycloalkyl and 3- to 8- membered heterocycloalkyl, wherein R^{52} and R^{53}, together with the nitrogen atom to which they are bound are optionally joined to form a 5- to 7-membered heterocyclic ring; and

R^{54} is independently chosen from acyl, C_1-C_6-alkyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C_3-C_8 cycloalkyl and 3- to 8-membered heterocycloalkyl in the manufacture of a medicament for treating a neurodegenerative disease.

[0020d] The present invention also provides use of a compound having a structure according to Formula (I):



(I)

or a salt or solvate thereof,
wherein

ring A is 5-membered heteroaryl comprising a sulfur atom, wherein the heteroaryl is optionally substituted with 1 or 2 substituents independently chosen from alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, C_3-C_{10}-cycloalkyl, 3- to 8-membered heterocycloalkyl, aryl, 5- or 6-membered heteroaryl, CN, halogen, OR^{12}, SR^{12}, $NR^{12}R^{13}$, $C(O)R^{14}$, $C(O)NR^{12}R^{13}$, $OC(O)NR^{12}R^{13}$, $C(O)OR^{12}$, $NR^{15}C(O)R^{14}$, $NR^{15}C(O)OR^{12}$, $NR^{15}C(O)NR^{12}R^{13}$, $NR^{15}C(S)NR^{12}R^{13}$, $NR^{15}S(O)_2R^{14}$, $S(O)_2NR^{12}R^{13}$, $S(O)R^{14}$ and $S(O)_2R^{14}$,

wherein

R^{12}, R^{13} and R^{15} are independently chosen from H, acyl, C_1-C_6-alkyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C_3-C_8 cycloalkyl and 3- to 8-membered heterocycloalkyl, or R^{12} and R^{13},

together with the nitrogen atom to which they are bound form a 5- to 7- membered heterocyclic ring; and

R^{14} is chosen from acyl, C_1-C_6-alkyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6- membered heteroaryl, C_3-C_8 cycloalkyl and 3- to 8-membered heterocycloalkyl;

C^a and C^b are carbon atoms, which are adjacent to each other and are part of ring A;

Z is 5- or 6-membered heteroaryl;

R^5 is chosen from H, acyl, C_1-Ce alkyl, and C3-C6 cycloalkyl;

W is chosen from C_1-C_4 alkylene, wherein the alkylene is optionally substituted with 1 – 4 substituents independently chosen from alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, C_3-C_6-cycloalkyl, 3- to 8-membered heterocycloalkyl, aryl, 5- or 6-membered heteroaryl, CN, halogen, OR^{42}, SR^{42}, $NR^{42}R^{43}$, $C(O)R^{44}$, $C(O)NR^{42}R^{43}$, $OC(O)NR^{42}R^{43}$, $C(O)OR^{42}$, $NR^{45}C(O)R^{44}$, $NR^{45}C(O)OR^{42}$, $NR^{45}C(O)NR^{42}R^{43}$, $NR^{45}C(S)NR^{42}R^{43}$, $NR^{45}S(O)_2R^{44}$, $S(O)_2NR^{42}R^{43}$, $S(O)R^{44}$, and $S(O)_2R^{44}$,
wherein
R^{42}, R^{43} and R^{45} are members independently chosen from H, acyl, C_1-C_6-alkyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C_3-C_8 cycloalkyl and 3- to 8-membered heterocycloalkyl, wherein R^{42} and R^{43}, together with the nitrogen atom to which they are bound are optionally joined to form a 5- to 7-membered heterocyclic ring; and

R^{44} is independently chosen from acyl, C_1-C_6-alkyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C_3-C_8 cycloalkyl and 3- to 8-membered heterocycloalkyl;

Cy is chosen from cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, wherein the cycloalkyl, heterocycloalkyl, aryl or heteroaryl is optionally substituted with 1 - 6 substituents independently chosen from substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, haloalkyl, substituted or unsubstituted heteroalkyl , substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl , substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, CN, halogen, OR^{52}, SR^{52}, $NR^{52}R^{53}$, $C(O)R^{54}$, $C(O)NR^{52}R^{53}$, $OC(O)NR^{52}R^{53}$, $C(O)OR^{52}$, $NR^{55}C(O)R^{54}$, $NR^{55}C(O)OR^{52}$, $NR^{55}C(O)NR^{52}R^{53}$, $NR^{55}C(S)NR^{52}R^{53}$, $NR^{55}S(O)_2R^{54}$, $S(O)_2NR^{52}R^{53}$, $S(O)R^{54}$ and $S(O)_2R^{54}$,

wherein

R^{52}, R^{53} and R^{55} are independently chosen from H, acyl, C_1-C_6-alkyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C_3-C_8 cycloalkyl and 3- to 8-membered heterocycloalkyl, wherein R^{52} and R^{53}, together with the nitrogen atom to which they are bound are optionally joined to form a 5- to 7-membered heterocyclic ring; and

R^{54} is independently chosen from acyl, C_1-C_6-alkyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C_3-C_8 cycloalkyl and 3- to 8-membered heterocycloalkyl in the manufacture of a medicament for reducing p-cjun concentration in brain tissue of a subject in need thereof.

DETAILED DESCRIPTION OF THE DISCLOSURE

Definitions


[0021] The definitions and explanations below are for the terms as used throughout this entire document including both the specification and the claims. Throughout the

N-(4-chloro-3-(1-methyl-1H-1,2,4-triazol-3-yl)thiophen-2-yl)-2-(2-oxo-7-(trifluoromethyl)-1,6-naphthyridin-1(2H)-yl)acetamide,

or a pharmaceutically acceptable salt thereof.

18. A pharmaceutical composition comprising a compound according to claim 1, 7, 12 or 17 and a pharmaceutically acceptable carrier.

19. Use of a pharmaceutically effective amount of a compound having a structure according to Formula (I):



(I)

or a salt or solvate thereof,

wherein

ring A is 5-membered heteroaryl comprising a sulfur atom, wherein the heteroaryl is optionally substituted with 1 or 2 substituents independently chosen from alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, C_3-C_{10}-cycloalkyl, 3- to 8-membered heterocycloalkyl, aryl, 5- or 6-membered heteroaryl, CN, halogen, OR^{12}, SR^{12}, $NR^{12}R^{13}$, $C(O)R^{14}$, $C(O)NR^{12}R^{13}$, $OC(O)NR^{12}R^{13}$, $C(O)OR^{12}$, $NR^{15}C(O)R^{14}$, $NR^{15}C(O)OR^{12}$, $NR^{15}C(O)NR^{12}R^{13}$, $NR^{15}C(S)NR^{12}R^{13}$, $NR^{15}S(O)_2R^{14}$, $S(O)_2NR^{12}R^{13}$, $S(O)R^{14}$ and $S(O)_2R^{14}$,

wherein

R^{12}, R^{13} and R^{15} are independently chosen from H, acyl, C_1-C_6-alkyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C_3-C_8 cycloalkyl and 3- to 8-membered heterocycloalkyl, or R^{12} and R^{13}, together with the nitrogen atom to which they are bound form a 5- to 7-membered heterocyclic ring; and

R^{52}, R^{53} and R^{55} are independently chosen from H, acyl, C_1-C_6-alkyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C_3-C_8 cycloalkyl and 3- to 8- membered heterocycloalkyl, wherein R^{52} and R^{53}, together with the nitrogen atom to which they are bound are optionally joined to form a 5- to 7-membered heterocyclic ring; and

R^{54} is independently chosen from acyl, C_1-C_6-alkyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C_3-C_8 cycloalkyl and 3- to 8-membered heterocycloalkyl in the manufacture of a medicament for treating a neurodegenerative disease.


20. The use of claim 19, wherein Z is a 5- or 6-membered heteroaryl, with the proviso that when ring A is thiophene, then Z is not a heteroaryl chosen from benzoimidazole, thiazole, and benzothiazole; when ring A is thiazole, then Z is not benzoimidazole; when ring A is thiophene, then Z is not substituted oxadiazole; and when ring A is thiophene, then Z is not pyrimidinone.

21. The use of claim 19, wherein the neurodegenerative disease is chosen from Alzheimer's disease, diffuse Lewy body type of Alzheimer's disease, Parkinson's disease, Down syndrome, dementia, mild cognitive impairment (MCI), amyotrophic lateral sclerosis (ALS), traumatic brain injuries, cerebral ischemic brain damage, ischemic or hemorrhaging stroke, hereditary cerebral hemorrhage with amyloidosis of the dutch-type and cerebral amyloid angiopathy.

22. The use of claim 19, wherein said neurodegenerative disease is Alzheimer's disease, diffuse Lewy body type of Alzheimer's disease, or mild cognitive impairment (MCI), and the mammalian subject is a human.

23. Use of a compound

having a structure according to Formula (I):



(I)

or a salt or solvate thereof,
wherein

R^{44} is independently chosen from acyl, C_1-C_6-alkyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C_3-C_8 cycloalkyl and 3- to 8-membered heterocycloalkyl;

Cy is chosen from cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, wherein the cycloalkyl, heterocycloalkyl, aryl or heteroaryl is optionally substituted with 1 - 6 substituents independently chosen from substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, haloalkyl, substituted or unsubstituted heteroalkyl , substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl , substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, CN, halogen, OR^{52}, SR^{52}, $NR^{52}R^{53}$, $C(O)R^{54}$, $C(O)NR^{52}R^{53}$, $OC(O)NR^{52}R^{53}$, $C(O)OR^{52}$, $NR^{55}C(O)R^{54}$, $NR^{55}C(O)OR^{52}$, $NR^{55}C(O)NR^{52}R^{53}$, $NR^{55}C(S)NR^{52}R^{53}$, $NR^{55}S(O)_2R^{54}$, $S(O)_2NR^{52}R^{53}$, $S(O)R^{54}$ and $S(O)_2R^{54}$,

wherein

R^{52}, R^{53} and R^{55} are independently chosen from H, acyl, C_1-C_6-alkyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C_3-C_8 cycloalkyl and 3- to 8-membered heterocycloalkyl, wherein R^{52} and R^{53}, together with the nitrogen atom to which they are bound are optionally joined to form a 5- to 7-membered heterocyclic ring; and

R^{54} is independently chosen from acyl, C_1-C_6-alkyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C_3-C_8 cycloalkyl and 3- to 8-membered heterocycloalkyl in the manufacture of a medicament for reducing p-cjun concentration in brain tissue of a subject in need thereof.

24. The use of claim 23, wherein Z is a 5- or 6-membered heteroaryl, with the proviso that when ring A is thiophene, then Z is not a heteroaryl chosen from benzoimidazole, thiazole, and benzothiazole; when ring A is thiazole, then Z is not benzoimidazole; when ring A is thiophene, then Z is not substituted oxadiazole; and when ring A is thiophene, then Z is not pyrimidinone.

25. The use of claim 23, further comprising administering an excitatory amino acid.

26. The use of claim 25, wherein the excitatory amino acid is kainic acid.

27. Use of a compound in an in vitro assay measuring kinase activity, said compound having a structure according to Formula (I):